Stock Ideas
New
Stocks
Funds
Screener
Sectors
Watchlists
LUNG

LUNG - Pulmonx Corp Stock Price, Fair Value and News

5.78USD-0.48 (-7.67%)Delayed

Market Summary

LUNG
USD5.78-0.48
Delayed
-7.67%

LUNG Stock Price

View Fullscreen

LUNG RSI Chart

LUNG Valuation

Market Cap

224.4M

Price/Earnings (Trailing)

-3.82

Price/Sales (Trailing)

3.07

EV/EBITDA

-3.41

Price/Free Cashflow

-5.91

LUNG Price/Sales (Trailing)

LUNG Profitability

Operating Margin

100.00%

EBT Margin

-79.59%

Return on Equity

-53.15%

Return on Assets

-35.69%

Free Cashflow Yield

-16.93%

LUNG Fundamentals

LUNG Revenue

Revenue (TTM)

73.0M

Rev. Growth (Yr)

29.71%

Rev. Growth (Qtr)

-2.2%

LUNG Earnings

Earnings (TTM)

-58.7M

Earnings Growth (Yr)

13.31%

Earnings Growth (Qtr)

1%

Breaking Down LUNG Revenue

Last 7 days

-16.7%

Last 30 days

-38.0%

Last 90 days

-35.4%

Trailing 12 Months

-54.9%

How does LUNG drawdown profile look like?

LUNG Financial Health

Current Ratio

6.95

Debt/Equity

0.29

Debt/Cashflow

-1.15

LUNG Investor Care

Shares Dilution (1Y)

2.83%

Diluted EPS (TTM)

-1.54

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs
Net sales
YearQ1Q2Q3Q4
202473.0M000
202357.4M60.7M64.8M68.7M
202250.0M51.7M51.9M53.7M
202133.4M41.9M44.5M48.4M
202035.4M31.7M33.3M32.7M
201923.2M26.3M29.4M32.6M
201800020.0M

Tracking the Latest Insider Buys and Sells of Pulmonx Corp

Filter Transactions
Datesorted ascendingNameBuy/Sell$ ValueAvg. Price# SharesTitle
Jun 03, 2024
mead dana g jr.
acquired
-
-
15,216
-
Jun 03, 2024
sullivan tiffany
acquired
-
-
15,216
-
Jun 03, 2024
lehman david aaron
sold
-38,160
6.97
-5,475
general counsel
Jun 03, 2024
rose geoffrey beran
sold
-29,950
6.97
-4,297
chief commercial officer
Jun 03, 2024
burns thomas william
acquired
-
-
15,216
-
Jun 03, 2024
florin daniel p
acquired
-
-
15,216
-
Jun 03, 2024
french glendon e. iii
acquired
-
-
15,216
-
Jun 03, 2024
melenikiotou georgia
acquired
-
-
15,216
-
Jun 03, 2024
ferrari richard
acquired
-
-
15,216
-
May 22, 2024
rose geoffrey beran
sold
-10,312
8.71
-1,184
chief commercial officer

1–10 of 50

Which funds bought or sold LUNG recently?

View All Details
Datesorted ascendingFund NameType% Chg$ Change$ Held% Portfolio
May 16, 2024
COMERICA BANK
unchanged
-
-1,305
3,476
-%
May 16, 2024
CALIFORNIA STATE TEACHERS RETIREMENT SYSTEM
reduced
-4.87
-143,566
321,975
-%
May 16, 2024
JANE STREET GROUP, LLC
sold off
-100
-990,879
-
-%
May 15, 2024
ALGERT GLOBAL LLC
reduced
-36.1
-614,000
533,000
0.02%
May 15, 2024
ABG-WTT Global Life Science Capital Partners GP Ltd
unchanged
-
-209,510
558,091
1.34%
May 15, 2024
Divisadero Street Capital Management, LP
reduced
-85.18
-16,006,600
1,932,540
0.45%
May 15, 2024
Voya Investment Management LLC
reduced
-19.67
-80,270
112,714
-%
May 15, 2024
Aquatic Capital Management LLC
reduced
-16.91
-139,863
214,137
0.01%
May 15, 2024
PDT Partners, LLC
added
122
248,726
651,588
0.06%
May 15, 2024
TWO SIGMA INVESTMENTS, LP
reduced
-46.00
-1,308,240
845,748
-%

1–10 of 47

Are Funds Buying or Selling LUNG?

Are funds buying LUNG calls or puts?
Calls
Puts
No. of funds holding Calls - Puts
Net Call Options
No. of funds that own LUNG
No. of Funds

Unveiling Pulmonx Corp's Major ShareHolders

Date FiledName of FilerPercent of ClassNo. of SharesForm Type
Mar 11, 2024
fmr llc
-
0
SC 13G/A
Feb 29, 2024
point72 asset management, l.p.
5.0%
1,913,561
SC 13G
Feb 14, 2024
point72 asset management, l.p.
4.0%
1,546,089
SC 13G/A
Feb 13, 2024
vanguard group inc
5.39%
2,066,442
SC 13G/A
Feb 13, 2024
champlain investment partners, llc
0.00%
0
SC 13G/A
Feb 12, 2024
primecap management co/ca/
14.74%
5,646,451
SC 13G/A
Feb 12, 2024
flynn james e
0.02%
6,009
SC 13G/A
Feb 09, 2024
morgan stanley
5.4%
2,061,758
SC 13G/A
Feb 09, 2024
fmr llc
-
0
SC 13G
Jan 25, 2024
blackrock inc.
8.1%
3,117,063
SC 13G/A

Recent SEC filings of Pulmonx Corp

View All Filings
Date Filed Form Type Document
Jun 05, 2024
4
Insider Trading
Jun 05, 2024
4
Insider Trading
Jun 05, 2024
4
Insider Trading
Jun 05, 2024
4
Insider Trading
Jun 05, 2024
4
Insider Trading
Jun 05, 2024
4
Insider Trading
Jun 05, 2024
4
Insider Trading
Jun 05, 2024
4
Insider Trading
Jun 05, 2024
4
Insider Trading
May 31, 2024
SD
SD

Peers (Alternatives to Pulmonx Corp)

NameMkt Capsorted ascendingRevenuePrice %, 1MReturns, 1YP/EP/SRev 1-YrInc 1-Yr
LARGE-CAP
180.4B
40.3B
-0.87% -1.28%
32.05
4.47
-2.84% -3.00%
67.6B
19.7B
-1.49% -8.74%
50.68
3.43
4.82% -17.56%
19.3B
3.9B
-8.68% -23.17%
41.69
4.92
5.72% 46.72%
17.2B
14.9B
-4.71% -24.07%
6.49
1.16
2.98% 207.68%
MID-CAP
9.6B
3.5B
-1.72% 24.73%
30.66
2.71
6.16% 35.06%
8.4B
12.4B
-11.97% -13.19%
21.71
0.68
-0.93% -18.83%
8.1B
2.6B
-6.15% -25.48%
-24.99
3.09
-6.25% -68.58%
5.4B
3.9B
-7.61% -31.99%
-56.77
1.38
0.23% 90.80%
3.4B
387.1M
-0.71% 28.31%
-215.21
8.86
30.82% 65.57%
2.0B
6.6B
-12.43% -18.98%
10.47
0.31
2.78% -0.87%
SMALL-CAP
1.5B
3.2B
15.14% 13.53%
-2.17
0.46
7.94% -1695.32%
390.3M
169.3M
0.92% -1.83%
-5.08
2.31
7.49% -244.90%
246.7M
324.0M
-3.14% -43.23%
-1.28
0.76
-3.19% -337.41%
50.2M
50.5M
2.84% -79.14%
-2.2
1
14.25% -10.06%
1.8M
3.7M
75.00% -80.56%
-0.15
0.49
5.77% 8.23%

Pulmonx Corp News

Latest updates
MarketBeat12 Jun 202407:36 pm

Pulmonx Corp Earnings Report: Key Takeaways & Analysis

Income Statement (Last 12 Months)
Income Statement (Quarterly)
(In Thousands)
(*) denotes actual numbers (not divided by Thousands)
Description(%) Q/Q2024Q12023Q42023Q32023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q42020Q32020Q22020Q12019Q42019Q32019Q22019Q1
Revenue-2.2%18,854,00019,278,00017,668,00017,194,00014,535,00015,425,00013,502,00013,950,00010,785,00013,708,00013,261,00012,203,0009,244,0009,830,00010,612,0003,673,0008,618,00010,347,0009,104,0007,366,0005,778,000
Gross Profit-2.2%14,078,00014,400,00013,029,00012,734,00010,589,00011,184,00010,152,00010,418,0008,111,00010,251,0009,739,0009,029,0006,611,0007,078,0007,462,0001,012,0005,650,0007,337,0006,407,0004,953,0003,717,000
Operating Expenses1.0%28,614,00028,319,50028,205,00029,173,00026,989,00025,811,00024,083,00024,829,00023,779,00022,617,00019,501,00021,711,00019,105,00016,432,00012,810,00012,538,00011,754,000-10,020,000--
  S&GA Expenses-0.1%24,404,00024,423,00023,985,00023,463,00022,736,00021,908,00019,717,00021,235,00020,245,00018,909,00016,686,00018,205,00016,071,00013,960,00010,813,00011,112,00010,189,000-8,621,000--
  R&D Expenses8.0%4,210,0003,896,5004,220,0005,710,0004,253,0003,903,0004,366,0003,594,0003,534,0003,708,0002,815,0003,506,0003,034,0002,472,0001,997,0001,426,0001,565,000-1,399,000--
EBITDA Margin10.0%-0.75-0.83-0.89-0.95-0.99-1.07-1.09-1.01-1.02-0.98-0.98-0.87---------
Interest Expenses-2.4%883,000904,500893,000864,000571,000359,000286,000223,000198,000199,000207,000206,000217,000267,0001,103,000912,000899,000-460,000--
Income Taxes-26.2%200,000271,000100,000100,000100,000246,000-40,00067,000135,50044,00080,000100,00017,00049,00056,00087,000-89,000--
Earnings Before Taxes0.6%-13,563,000-13,640,000-14,841,000-16,055,000-15,736,000-14,037,000-14,172,000-14,600,000-15,761,000-12,854,000-10,137,000-12,882,000-12,445,000-9,276,000-3,811,000-11,855,000-7,076,000--4,246,000--
EBT Margin9.3%-0.80-0.88-0.94-0.99-1.02-1.09-1.10-1.03-1.03-1.00-1.00-0.92---------
Net Income1.0%-13,749,000-13,888,000-14,900,000-16,195,000-15,860,000-14,283,000-14,172,000-14,640,000-15,828,000-13,006,000-10,181,000-12,962,000-12,512,000-9,297,000-3,860,000-11,911,000-7,163,000-4,669,000-4,335,000-5,571,000-6,128,000
Net Income Margin9.2%-0.80-0.89-0.94-1.00-1.03-1.10-1.11-1.04-1.04-1.01-1.01-0.92---------
Free Cashflow-41.8%-12,246,000-8,639,000-9,192,000-7,910,000-12,705,000-9,976,000-10,989,000-9,889,000-15,564,000-11,836,000-9,920,000-13,389,000---------
Balance Sheet
(In Millions)
Balance Sheet
(In Millions)
(*) denotes actual numbers (not divided by Millions)
Description(%) Q/Q2024Q12023Q42023Q32023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q42020Q32019Q4
Assets-7.4%16517818519320119420221322323524724925526471.0054.00
  Current Assets-1.7%14815014716418116918319320120822823323925056.0041.00
    Cash Equivalents-16.0%70.0084.0095.0010211010211212212914918819920923240.0015.00
  Inventory2.9%17.0017.0016.0016.0016.0015.0016.0019.0018.0016.0015.0013.0012.0011.009.006.00
  Net PPE4.7%4.004.004.004.004.005.005.005.005.005.005.003.002.001.001.001.00
  Goodwill0%2.002.002.002.002.002.002.002.002.002.002.002.002.002.002.002.00
Liabilities-9.0%54.0059.0059.0059.0057.0040.0039.0041.0041.0042.0044.0040.0039.0038.0071.0036.00
  Current Liabilities-8.0%21.0023.0020.0020.0017.0018.0022.0020.0018.0018.0022.0017.0014.0013.0015.0014.00
  Short Term Borrowings142.7%5.002.000.000.000.000.005.003.001.000.00------
  Long Term Debt-8.8%32.0035.0037.0037.0037.0017.0012.0014.0017.0017.00----30.00-
    LT Debt, Current-----------3.002.000.00---
    LT Debt, Non Current-8.8%32.0035.0037.0037.0037.0017.0012.0014.0017.0017.00------
Shareholder's Equity-6.6%110118126134144154163172182193203209216226--
  Retained Earnings-3.3%-424-411-397-382-366-350-336-321-307-291-278-268-255-242-233-210
  Additional Paid-In Capital1.3%53352752151450850349849348848348047647046725.0022.00
Shares Outstanding0.8%39.0039.0038.0038.0038.0038.0037.0037.0037.0037.0036.0036.00----
Float----479---523---1,200----
Cashflow (Last 12 Months)
(In Thousands)
Cashflow (Quarterly)
(In Thousands)
(*) denotes actual numbers (not divided by Thousands)
Description(%) Q/Q2024Q12023Q42023Q32023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q42020Q32020Q22020Q12019Q42019Q32018Q4
Cashflow From Operations-39.8%-11,795-8,439-8,626-7,935-12,600-9,800-10,710-9,590-15,000-10,688-8,338-12,690-9,672-7,262-5,871-7,700-9,800---
  Share Based Compensation1.3%5,6735,5986,0035,8624,6384,2474,3024,3833,5133,0122,9382,3122,2682,311518159209---
Cashflow From Investing9.0%-2,507-2,755987-813574-72744.002,080-5,622-29,124-3,414-1,186-12,531-693-76.003,43910,024---
Cashflow From Financing4982.4%86417.0057192.0020,72067.009061311,3151501,0003,29313.00199,7652,35931,3991,308---
  Buy Backs------27.00------26.00-----12.00-
Get Full Access to Grufity – and Unlimited Downloads
Gain full access to fair value, watchlists, stock screener, unlimited page visits, and additional features by joining as a member today for just $1.99.
Try For Just $1.99

LUNG Income Statement

2024-03-31
Condensed Consolidated Statements of Operations and Comprehensive Loss - USD ($)
$ in Thousands
3 Months Ended
Mar. 31, 2024
Mar. 31, 2023
Income Statement [Abstract]  
Revenue$ 18,854$ 14,535
Cost of goods sold4,7763,946
Gross profit14,07810,589
Operating expenses  
Research and development4,2104,253
Selling, general and administrative24,40422,736
Total operating expenses28,61426,989
Loss from operations(14,536)(16,400)
Interest income1,4411,127
Interest expense(883)(571)
Other income, net415108
Net loss before tax(13,563)(15,736)
Income tax expense186124
Net loss(13,749)(15,860)
Other comprehensive (loss) income  
Currency translation adjustment(549)72
Change in unrealized (losses) gains on marketable securities(128)173
Total other comprehensive (loss) income(677)245
Comprehensive loss$ (14,426)$ (15,615)
Net loss per share attributable to common stockholders, basic (in dollars per share)$ (0.36)$ (0.42)
Net loss per share attributable to common stockholders, diluted (in dollars per share)$ (0.36)$ (0.42)
Weighted-average shares used in computing net loss per share attributable to common stockholders, basic (in shares)38,636,02937,572,382
Weighted-average shares used in computing net loss per share attributable to common stockholders, diluted (in shares)38,636,02937,572,382

LUNG Balance Sheet

2024-03-31
Condensed Consolidated Balance Sheets - USD ($)
$ in Thousands
Mar. 31, 2024
Dec. 31, 2023
Current assets  
Cash and cash equivalents$ 70,158$ 83,547
Restricted cash236237
Short-term marketable securities45,97333,555
Accounts receivable, net10,52212,105
Inventory17,22816,743
Prepaid expenses and other current assets3,8194,235
Total current assets147,936150,422
Long-term marketable securities4,29314,390
Long-term inventory2,5222,580
Property and equipment, net4,2184,028
Goodwill2,3332,333
Intangible assets, net031
Right of use assets2,7053,406
Other long-term assets577591
Total assets164,584177,781
Current liabilities  
Accounts payable3,1251,497
Accrued liabilities10,07116,234
Income taxes payable6793
Deferred revenue110104
Short-term debt5,2312,155
Current lease liabilities2,6903,074
Total current liabilities21,29423,157
Deferred tax liability140114
Long-term lease liabilities6501,106
Long-term debt32,00235,089
Total liabilities54,08659,466
Commitments and contingencies (Note 8)
Stockholders’ equity  
Preferred stock, $0.001 par value, 10,000,000 shares authorized; no shares issued and outstanding as of March 31, 2024 and December 31, 202300
Common stock, $0.001 par value, 200,000,000 shares authorized as of March 31, 2024 and December 31, 2023; 38,812,175 shares issued and outstanding as of March 31, 2024 and 38,516,383 shares issued and outstanding as of December 31, 20233939
Additional paid-in capital533,406526,797
Accumulated other comprehensive income1,9632,640
Accumulated deficit(424,910)(411,161)
Total stockholders’ equity110,498118,315
Total liabilities and stockholders’ equity$ 164,584$ 177,781
LUNG
Pulmonx Corporation, a commercial-stage medical technology company, provides minimally invasive devices for the treatment of chronic obstructive pulmonary diseases. It offers Zephyr Endobronchial Valve, a solution for the treatment of patients with hyperinflation associated with severe emphysema; and Chartis Pulmonary Assessment System, a balloon catheter and console system with flow and pressure sensors that are used to assess the presence of collateral ventilation. The company also provides StratX Lung Analysis Platform, a cloud-based quantitative computed tomography analysis service that offers information on emphysema destruction, fissure completeness, and lobar volume to help identify target lobes for the treatment with Zephyr Valves. It serves emphysema patients in the United States, Europe, the Middle East, Africa, the Asia-Pacific, and internationally. The company was formerly known as Pulmonx and changed its name to Pulmonx Corporation in December 2013. The company was incorporated in 1995 and is headquartered in Redwood City, California.
 CEO
 WEBSITEhttps://pulmonx.com
 INDUSTRYMedical Instruments & Supplies
 EMPLOYEES269

Pulmonx Corp Frequently Asked Questions


What is the ticker symbol for Pulmonx Corp? What does LUNG stand for in stocks?

LUNG is the stock ticker symbol of Pulmonx Corp. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Pulmonx Corp (LUNG)?

As of Fri Jun 14 2024, market cap of Pulmonx Corp is 224.36 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of LUNG stock?

You can check LUNG's fair value in chart for subscribers.

What is the fair value of LUNG stock?

You can check LUNG's fair value in chart for subscribers. The fair value of Pulmonx Corp is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of Pulmonx Corp is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for LUNG so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is Pulmonx Corp a good stock to buy?

The fair value guage provides a quick view whether LUNG is over valued or under valued. Whether Pulmonx Corp is cheap or expensive depends on the assumptions which impact Pulmonx Corp's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for LUNG.

What is Pulmonx Corp's Price to Earnings (PE) and Price to sales (PS) ratio?

As of Fri Jun 14 2024, LUNG's PE ratio (Price to Earnings) is -3.82 and Price to Sales (PS) ratio is 3.07. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. LUNG PE ratio will change depending on the future growth rate expectations of investors.